3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Completed
3
Withdrawn
2
Recruiting
2
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
2
Conditions
Lymphoma, Large B-Cell, Diffuse
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Recurrence
4
Burkitt Lymphoma
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Neoplasm, Residual
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Interventions
Cyclophosphamide
118
Peripheral Blood Stem Cell Transplantation
67
Filgrastim
60
Etoposide
60
Rituximab
54
fludarabine phosphate
50
Vincristine
46
Radiotherapy
46
Methotrexate
46
Cytarabine
44
Doxorubicin
40
Cyclosporine
35
Mycophenolic Acid
33
Busulfan
33
Prednisone
32
Whole-Body Irradiation
31
Tacrolimus
28
Antilymphocyte Serum
28
Melphalan
27
Dexamethasone
26
Methylprednisolone
22
Leucovorin
19
Carmustine
18
Granulocyte Colony-Stimulating Factor
17
Calcium Dobesilate
16
Ifosfamide
15
Psychiatric Rehabilitation
13
Cord Blood Stem Cell Transplantation
13
sargramostim
12
merphos
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Burkitt Lymphoma
×
tisagenlecleucel
×
Clear all
NCT03610724
2024-06-20
BIANCA
Novartis
Phase 2
Completed
34 enrolled
19 charts
NCT02435849
2024-02-13
ELIANA
Novartis
Phase 2
Completed
80 enrolled
39 charts
NCT02228096
2020-11-23
ENSIGN
Novartis
Phase 2
Completed
75 enrolled
41 charts